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Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitinated
inclusions (FTLD-U) are major neurodegenerative diseases with TDP-43 pathology. Here we investi-
gated the effects of methylene blue (MB) and dimebon, two compounds that have been reported to
be beneﬁcial in phase II clinical trials of Alzheimer’s disease (AD), on the formation of TDP-43 aggre-
gates in SH-SY5Y cells. Following treatment with 0.05 lMMB or 5 lM dimebon, the number of TDP-
43 aggregates was reduced by 50% and 45%, respectively. The combined use of MB and dimebon
resulted in a 80% reduction in the number. These ﬁndings were conﬁrmed by immunoblot analysis.
The results indicate that MB and dimebon may be useful for the treatment of ALS, FTLD-U and other
TDP-43 proteinopathies.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction of Guam [11], argyrophilic grain disease [12], Huntington’s diseaseAmyotrophic lateral sclerosis (ALS) is a neurodegenerative dis-
ease that is characterized by progressive weakness and muscle
wasting, and for which no effective therapies exist. Frontotemporal
lobar degeneration (FTLD) is the second most common form of
dementia after Alzheimer’s disease (AD) in the population below
the age of 65 years. In many cases with these disorders, ubiquitin
(Ub)-positive, tau-negative intracytoplasmic inclusions form in
nerve cells and glial cells. TAR DNA binding protein of 43 kDa
(TDP-43) is the major component of these inclusions [1–3]. Bio-
chemical and histological analyses demonstrated that TDP-43
accumulates in brain and spinal cord in a hyperphosphorylated
and ﬁbrillar form [4]. Furthermore, missense mutations in the
TDP-43 gene have been identiﬁed in familial cases of ALS and
ALS with FTLD-U [5–9]. Together, these ﬁndings indicate that dys-
function of TDP-43 is central to the etiology and pathogenesis of
ALS and FTLD-U. In addition, TDP-43 has also been found to accu-
mulate in other neurodegenerative disorders, including AD,
dementia with Lewy bodies [10], Parkinsonism-dementia complexchemical Societies. Published by E[13], Perry syndrome [14] and familial British dementia [15].
Inhibition of the aggregation of TDP-43 and promotion of its
clearance are considered to be major therapeutic avenues for ALS
and FTLD-U. As for other neurodegenerative diseases, current tools
include antibodies, synthetic peptides, molecular chaperones and
chemical compounds. Of the latter, methylene blue (MB) and
dimebon have recently been reported to have signiﬁcant beneﬁcial
effects in phase II clinical trials of AD [16,17]. MB is a phenothia-
zine compound that has been used for treating methemoglobine-
mia [18,19], inhibiting nitric oxide synthase [20], reducing nGMP
[21], enhancing b-oxydation in mitochondria [22], inhibiting of
noradrenaline re-uptake [23] and enhancing brain mitochondrial
cytochrome oxidase activity [24,25]. It has also been shown to in-
hibit AD-like Ab and tau aggregation in vitro [26,27]. Dimebon is a
non-selective anti-histaminergic compound that was in clinical use
for many years before more selective agents became available [28].
It has been reported to inhibit butyrylcholinesterase, acetylcholin-
esterase, NMDA receptors, voltage-gated calcium channels, adren-
ergic receptors, histamine H1 receptors, histamine H2 receptors
and serotonin receptors, as well as to stabilize glutamate-induced
Ca2+ signals [29–31]. The effects of dimebon on pathological pro-
tein aggregation have not been studied in detail, but recently we
demonstrated that chronic administration of this drug reducedlsevier B.V. All rights reserved.
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opathy [32].
Here we investigated whether MB and dimebon can reduce the
formation of TDP-43 inclusions in SH-SY5Y cellular models. Signif-
icantly, the treatment of cells with each compound and their com-
bined application inhibited the formation of TDP-43 aggregates,
suggesting that MB and dimebon may be effective for the treat-
ment of ALS and FTLD-U.
2. Materials and methods
2.1. Antibodies
A polyclonal anti-TDP-43 antibody (anti-TDP-43) was pur-
chased from ProteinTech Group Inc. (10782-1-AP, Chicago, USA).Fig. 1. Immunohistochemical analysis of the effects of methylene blue (MB) and dimebon
TDP-43 inclusions were stained with anti-pS409/410 antibody and detected with Alexa
treated with control (DMSO + DW) (A), 0.05 lMMB + DW (B), 5 lM dimebon + DMSO (C)
43 aggregates. The number of cells with intracellular TDP-43 aggregates was counted an
(taken as 100%). Fluorescence intensity within an area of approximately 800 lm  80
calculated as the ratio of that of TO-PRO-3. At least 8 areas per sample were measuredA polyclonal antibody speciﬁc for phosphorylated TDP-43 (anti-
pS409/410) (available from Cosmo Bio Co., Tokyo, Japan) [4] and
an anti-Ub antibody (MAB1510, Chemicon, Billerica, USA) were
used for the evaluation of pathological forms of TDP-43.
2.2. TDP-43 cellular models and addition of compounds
To investigate the effects of MB and dimebon on the formation
of TDP-43 aggregates, we used two cellular models of TDP-43 pro-
teinopathy. The ﬁrst consists of SH-SY5Y cells expressing mutant
TDP-43 that lacks both the nuclear localization signal (NLS) and
residues 187–192 (DNLS&187-192). In these cells, round struc-
tures positive for both anti-pS409/410 and anti-Ub are observed
[33]. The second model consists of SH-SY5Y cells expressing an
aggregation-prone TDP-43 C-terminal fragment (residues 162–on the aggregation of TDP-43 in SH-SY5Y cells expressing TDP-43 (DNLS&187-192).
Fluor 488-labeled secondary antibody. Representative confocal images from cells
and 0.05 lMMB + 5 lM dimebon (D) are shown. (E) Quantitation of cells with TDP-
d expressed as the percentage of cells with aggregates in the absence of compound
0 lm was assessed by confocal microscopy. The intensity of Alexa Fluor 488 was
(n = 8–16). Data are means ± S.E.M. *P < 0.01 by Student’s t test.
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sion also results in the formation of anti-pS409/410- and anti-Ub-
positive inclusions. Six hours after transfection, the cells were trea-
ted with MB (Sigma–Aldrich, St. Louis, USA) dissolved in dimethyl
sulfoxide (DMSO), dimebon dissolved in sterile distilled water
(DW) or MB + dimebon and cultured for 3 days. As controls, cells
were treated with either DMSO or DW, or both of them for 3 days.
2.3. Immunohistochemical analysis
SH-SY5Y cells were grown on coverslips and transfected as de-
scribed [33]. After incubation for the indicated times, the cells were
ﬁxed with 4% paraformaldehyde and stained with anti-phosphory-
lated TDP-43 antibody pS409/410 or anti-Ub, followed by Alexa
Fluor 488- or Alexa Fluor 568-labeled IgG (Invitrogen, Carlsbad,Fig. 2. Immunohistochemical analysis of the effects of methylene blue (MB) and dime
fragment (162–414) as GFP fusion protein. TDP-43 inclusions were detected by ﬂuorescen
cells treated with control (DMSO + DW) (A), 0.05 lMMB + DW (B), 5 lM dimebon + DMS
TDP-43 aggregates. The intensity of ﬂuorescence of GFP was calculated as the ratio of
means ± S.E.M. *P < 0.01 by Student’s t test.USA). After washing, the cells were further incubated with TO-
PRO-3 (Invitrogen, Carlsbad, USA) to stain nuclear DNA. To quan-
tify the cells with TDP-43 aggregates, the laser power (at 488 nm
for detection of Alexa Fluor 488 and GFP) was adjusted, so that only
aggregates were detected as described [34]. Total intensity of ﬂuo-
rescence detected at the threshold laser power and that of TO-PRO-
3 ﬂuorescence, the latter corresponding to the total number of cells
in a given ﬁeld (approximately 800 lm  800 lm), were measured
with LSM5 Pascal v 4.0 software (Carl Zeiss), and the ratio of cells
with inclusions calculated.
2.4. Immunoblot analysis
Tris saline (TS)-soluble, Triton X-100 (TX)-soluble and Sarkosyl
(Sar)-soluble fractions, as well as the ﬁnal pellet, were prepared,bon on the aggregation of TDP-43 in SH-SY5Y cells expressing TDP-43 C-terminal
ce of GFP, when the laser power was adjusted. Representative confocal images from
O (C) and 0.05 lMMB + 5 lM dimebon (D) are shown. (E) Quantitation of cells with
that of TOPRO-3. At least 8 areas per sample were measured (n = 8–16). Data are
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pS409/410 antibodies, as described [33].
3. Results
3.1. Effects of MB and dimebon on the formation of TDP-43 inclusions
We ﬁrst investigated the cytotoxicity of MB and dimebon. SH-
SY5Y cells were treated with different concentrations of each com-
pound, cultured for 1 day, followed by growth measurements. No
toxic effects were detected with dimebon at concentrations of 1–
60 lM, whereas a signiﬁcant decrease in the number of cells was
observed with MB at concentrations greater than 0.1 lM. Cells
transfected with TDP-43 (DNLS&187-192) formed round intracel-
lular inclusion-like structures that were positive with both anti-
pS409/410 and anti-Ub antibodies, as reported previously [33]
(Fig. 1A). When the cells were treated for 3 days with MB, dimebon
or MB + dimebon, the number of TDP-43 inclusions was reduced
(Fig. 1B–D). Compared to controls, we observed a 50% reduction
in the number of inclusions with 0.05 lMMB, a 45% reduction with
5 lM dimebon and a 80% reduction with 0.05 lM MB + 5 lM
dimebon (Fig. 1B–E). The effects were concentration-dependent
and statistically signiﬁcant (Fig. 1E). Thus, 10 lM dimebon caused
a 60% reduction and 20 lM dimebon a 70% reduction in the num-
ber of TDP-43 inclusions. Similar results were obtained using a sec-
ond cellular model of TDP-43 proteinopathy (Fig. 2), which
expresses a C-terminal fragment (162–414) of TDP-43 as GFP fu-
sion protein [34]. Other anti-histaminergic compounds, including
promethazine hydrochloride, diphenhydramine hydrochloride
(H1 histamine receptor antagonist) and thioperamide maleate
(H3 histamine receptor antagonist) (Sigma–Aldrich, St. Louis,
USA), did not affect the number of TDP-43 aggregates (Fig. 3). Sim-
ilarly, two phenothiazine compounds tested, chlorpromazine
hydrochloride and perphenazine (Sigma–Aldrich, St. Louis, USA),
which failed to exert any effect on tau aggregation, did not affect
the aggregation of TDP-43 (Fig. 3)Fig. 3. Immunohistochemical analysis of the effects of three anti-histaminergic compoun
thioperamide maleate (Thiop), and two phenothiazine compounds, chlorpromazine hyd
cells expressing GFP-fused TDP-43 C-terminal fragment (162–414) as GFP fusion protein
aggregation was observed with these compounds. Promethazine hydrochloride and phen
higher concentrations.3.2. Immunoblot analysis of TDP-43 in cells treated with MB and
dimebon
The immunohistochemical results were conﬁrmed by immuno-
blotting. Cells expressing TDP-43 (DNLS&187-192) (data not
shown) or the C-terminal fragment (162–414) of TDP-43 (Fig. 4)
were sequentially extracted with TS, TX, and Sar, and the superna-
tants and pellets analyzed by immunoblotting. In cells transfected
with the C-terminal fragment (162–414) of TDP-43, phosphory-
lated C-terminal fragment of TDP-43 was detected in the Sar-insol-
uble fraction, as reported previously [34] (black arrowhead in Fig
4A). The levels of this band with slower gel mobility were reduced
when the cells were treated with MB, dimebon or MB + dimebon
(Fig. 4A and B). By contrast, similar levels of endogenous TDP-43
(black arrow in Fig. 4A) and expressed C-terminal fragment of
TDP-43 (white arrowhead in Fig. 4A) were detected in TS- and
TX-soluble fractions of control cells and of cells treated with MB
or dimebon, indicating that these compounds did not affect the
amount of TDP-43.
4. Discussion
In this study, we examined the effects of two compounds, MB
and dimebon, on the formation of abnormally phosphorylated
TDP-43 inclusions using SH-SY5Y cellular models. Both com-
pounds, when used singly or in combination, signiﬁcantly reduced
the number of TDP-43 aggregates. Although its mechanism of ac-
tion remains to be clariﬁed, it is reasonable to speculate that MB
may bind to dimers and oligomers of TDP-43 and thereby inhibit
ﬁbril formation, as has previously been demonstrated for the inhi-
bition of Ab and tau aggregation by MB in vitro [27]. The present
ﬁndings show, for the ﬁrst time, that MB can reduce protein aggre-
gation in cells.
In addition, we have identiﬁed dimebon as a compound capa-
ble of inhibiting the formation of abnormal inclusions of TDP-43.
In view of the recent demonstration of its efﬁcacy in a phase IIds, promethazine hydrochloride (PMT), diphenhydramine hydrochloride (DPH) and
rochloride (CPZ) and perphenazine (PZC) on the aggregation of TDP-43 in SH-SY5Y
. Quantitation of cells with TDP-43 aggregates is shown. No reduction in the TDP-43
othiazines were tested at 10 lM and 0.1 lM, respectively, because they were toxic at
Fig. 4. Immunoblot analysis of the effects of methylene blue (MB) and dimebon on the aggregation of TDP-43 in SH-SY5Y cells expressing GFP-tagged TDP-43 C-terminal
fragment (162–414). Tris saline (TS)-soluble material, Triton X-100 (TX)-soluble material, Sarkosyl (Sar)-soluble material and the remaining pellet (ppt) were prepared from
control cells and from cells treated with 0.05 lMMB, 5 lM dimebon or 0.05 lMMB + 5 lM dimebon, run on SDS–PAGE and immunoblotted with anti-TDP-43 antibody (A) or
anti-pS409/410 antibody (B). Abnormally phosphorylated TDP-43 C-terminal fragment (162–414) with a higher apparent molecular mass than the corresponding non-
phosphorylated fragment (white arrowhead) was detected by both antibodies (black arrowheads). Similar levels of the non-phosphorylated GFP-tagged C-terminal fragment
of TDP-43 (white arrowhead) and of endogenous TDP-43 (black arrow) were detected with the anti-TDP-43 antibody (A).
M. Yamashita et al. / FEBS Letters 583 (2009) 2419–2424 2423clinical trial, dimebon may well become a new drug for the treat-
ment of AD and other neurodegenerative diseases. Although there
have been some reports suggesting that dimebon may act as a
neuroprotective agent and prevent mitochondrial pore transition
in experimental models of AD [36] and Huntington’s disease
[30], its precise mode of action remains unknown. The present
study suggests that dimebon may act by reducing the production
or accumulation of abnormal protein aggregates. It remains to be
determined whether the effects on TDP-43 aggregation are of a
direct or an indirect nature. It will also be interesting to investi-
gate the effects of dimebon in existing [37] and future animal
models of TDP-43 proteinopathy. We could not detect a signiﬁ-
cant effect of dimebon on the in vitro assembly of recombinant
human a-synuclein into ﬁlaments and on the heparin-induced
assembly of recombinant human tau into ﬁlaments (data not
shown). The recent demonstration that dimebon reduces the
number of protein inclusions in a model synucleinopathy [32]
suggests that its effects may be indirect.
MB has been used for many years to treat a variety of condi-
tions, including methemoglobinemia [19], septic shock [20] and
depression [38]. It has recently been used in a phase II trial of AD[16]. Furthermore, MB has been reported to have activity as an en-
hancer of mitochondrial activity [24], and a recent study has re-
ported that it delays cellular senescence in cultured human
ﬁbroblasts [25]. However, high doses of MB are known to be toxic
and to cause the formation of Heinz bodies in erythrocytes in in-
fants [39]. A combination therapy, like the one used here, may
therefore be advantageous.
In conclusion, the present results showing a reduction in the
number of TDP-43 inclusions following the addition of MB and/or
dimebon to transfected SH-SY5Y cells suggest that these com-
pounds may be beneﬁcial for the treatment of ALS and FTLD-U.
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